HALEON US HOLDINGS — Patent Portfolio
1 drug with active patents · 41 active patents · 1 expired · 0 biologics with BPCIA exclusivity
Verdict The HALEON US HOLDINGS portfolio is moderately strong, with a significant cliff year in 2027 and $3,100 million in revenue at risk.
Portfolio overview The company's portfolio consists of a total of 2 drugs, with 1 of them having patents. The portfolio has a total of 42 US patents, with 41 active and 1 expired. The average vulnerability score is 61, indicating a moderate level of vulnerability. The portfolio has 2 ironclad patents and 9 vulnerable patents. Notably, there are no biologics in the portfolio.
Cliff calendar In 2027, 1 drug will lose exclusivity, including Arnuity Ellipta. This marks a significant cliff year for the company. Additionally, 5 drugs lose exclusivity in 2028 including sample names not provided.
Most exposed drugs The top drug facing near-term loss of exclusivity is Arnuity Ellipta, with an earliest active patent expiry date of 2027-06-14, an average vulnerability score of 61, and annual revenue of $3,100 million. This drug has a significant patent portfolio with 41 patents.
Biologic exclusivity There are no biologics in the portfolio, and therefore, there is no BPCIA 12-year reference product exclusivity to consider.
Strategic implications The company has $3,100 million in revenue at risk in the next 5 years. To mitigate this risk, the company may consider lifecycle moves such as subQ switches, label extensions, or combination filings to extend the life of its patents and maintain revenue.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Arnuity Ellipta (FLUTICASONE FUROATE)
Cliff 2027 · 1y-
US8511304
Vuln 83
2027-06-14
This patent protects a medicament dispenser for use with multiple elongate form medicament carriers, such as those used with Arnuity Ellipta.
-
US11116721
Vuln 83
2029-02-26
This patent provides novel pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth.
-
US8511304
Vuln 80
2027-06-14
This patent protects a medicament dispenser for use with multiple elongate form medicament carriers, such as those used with Arnuity Ellipta.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Other 16 patents
- Formulation 16 patents
- Method of Use 7 patents
- Composition of Matter 2 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track HALEON US HOLDINGS's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export